On Thursday, Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares inclined 0.43% to $0.352. With its recent share price change, SNTA market value has reached roughly $48.50M billion. Its most recent quarter balance sheet showed the company is standing at a 2.90 current ratio and possess 0.12 as debt to equity ratio. The stock’s performance in 1 month is -18.14% and its volatility for the same period is 10.88%.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
Exelon Corporation (NYSE:EXC)’s shares gained 0.36% to $27.79.
Constellation, a leading competitive energy and services company and the official preferred energy provider of the NHL, will match the carbon dioxide emissions of the 2016 Bridgestone NHL Winter Classic®, with energy generated from environmentally responsible renewable resources through Green-e® Energy Certified* Renewable Energy Certificates (RECs), minimizing the carbon footprint of one of the League’s premier events. In an effort to improvement fan awareness of responsible energy use, the game will also feature a pregame public service declaration featuring Stanley Cup® Champion Andrew Ference.
“Our partnership with Constellation advances the commitment of the National Hockey League to the promotion of responsible energy use,” NHL Commissioner Gary Bettman said. “Our teams and our fans all know our game was born in winter weather and that everyone benefits from actively preserving the environment that keeps our ponds frozen.”
As the NHL’s official preferred energy provider, Constellation works with the NHL to conduct energy efficiency analyses and recommend energy administration strategies for NHL arenas and team facilities. Through its partnership with Constellation, the NHL now ranks as the 20th largest user of green power in the U.S., according to the EPA’s Green Power Partnership, and was recognized with the 2015 Green Power Leadership Award from the U.S. Environmental Protection Agency (EPA) for its leadership, overall strategy, and impact on the green power market.
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Inovio Pharmaceuticals Inc (NASDAQ:INO)‘s shares dipped -4.00% to $6.72. The last trading range of Inovio Pharmaceuticals Inc (NASDAQ:INO) ranges between $6.69 and $7.02. The EPS of the company stands at $-0.31. The 52-week range shows that the stock reached higher at $10.83 while its lower range is $5.32 in the last 52-weeks. The average volume of the company is at 1.17 million with the Outstanding Shares of 72.18 million. The market capitalization of the company is $484.63 Million. The Beta of the company stands at 2.36 with the RSI (Relative Strength Index) of 46.55.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
